Icosapent ethyl does not reduce COVID-19 hospitalization, death despite favorable trends

icosapent ethyl does not reduce covid 19 hospitalization death despite favorable trends

Sumary of Icosapent ethyl does not reduce COVID-19 hospitalization, death despite favorable trends:

  • November 15, 2021 3 min read Source/Disclosures Published by: Source: Diaz R, et al.
  • LBS.06. Fish Oil and Cholesterol: Recipes for CVD Prevention?
  • Presented at: American Heart Association Scientific Sessions;
  • Data from the PREPARE-IT 2 study were presented at the American Heart Association Scientific Sessions.
  • The PREPARE-IT 1 study, presented at the European Society of Cardiology Congress in August, demonstrated high-dose icosapent ethyl for 60 days did not prevent incident SARS-CoV-2 infection among healthy participants who did not have prior known infection, with or without COVID-19 vaccination.
  • Bhatt The PREPARE-IT 2 study was an opportunity for researchers to assess an already-approved treatment that could potentially be easily deployed and repurposed for COVID-19-positive outpatients, a group without many treatment options, according to Cardiology Today Intervention Section Editor Deepak L.
  • Bhatt, MD, MPH, executive director of interventional cardiology programs at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.